Pathophysiology and Therapeutics of Cardiovascular Disease in Metabolic Syndrome

Author(s): Yabin Wang, Qiujun Yu, Yundai Chen, Feng Cao

Journal Name: Current Pharmaceutical Design

Volume 19 , Issue 27 , 2013

Become EABM
Become Reviewer
Call for Editor


The metabolic syndrome (MetS) is characterized by a cluster of cardiovascular risk factors, including central obesity, hyperglycemia, dyslipidemia and hypertension, which are highly associated with increased morbidity and mortality of cardiovascular diseases (CVD). The association between these metabolic disorders and the development of CVD is believed to be multifactorial, where insulin resistance, oxidative stress, low-grade inflammation and vascular maladaptation act as the major contributors. Therefore, multipronged therapeutic strategies should be taken for the management of patients with MetS. Lifestyle changes including weight control, healthy heart diet and regular exercises have been proposed as first line treatment to decrease CVD risks in MetS individuals. In addition, improving insulin resistance and glucose metabolism, controlling blood pressure as well as modulating dyslipidemia can also delay or reverse the progression of CVD in MetS. This review will first address the complicated interactions between MetS and CVD¸ followed by discussion about the optimal strategy in the prevention and treatment of CVD in MetS patients and the updated results from newly released clinical trials.

Keywords: Metabolic syndrome, cardiovascular disease, insulin resistance, obesity, diabetes, dyslipidemia.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2013
Published on: 24 June, 2013
Page: [4799 - 4805]
Pages: 7
DOI: 10.2174/1381612811319270002
Price: $65

Article Metrics

PDF: 25